TABLE 4.

Top 20 ADRs of Enfortumab vedotin and Erdafitinib.

Enfortumab vedotin (N = 6,205)		Erdafitinib (N = 2,758)
ADR	Report rate %	ADR	Report rate %
Neuropathy peripheral	5.12	Death	8.34
Rash	5.12	Diarrhoea	3.37
Fatigue	2.69	Off label use	3.30
Malignant neoplasm progression	2.40	Hyperphosphataemia	2.57
Diarrhoea	2.26	Disease progression	2.28
Pruritus	2.00	Transitional cell carcinoma	1.92
Asthenia	1.79	Mucosal inflammation	1.89
Hyperglycaemia	1.68	Stomatitis	1.81
Nausea	1.60	Dry mouth	1.74
Skin toxicity	1.37	Onycholysis	1.67
Off label use	1.35	Fatigue	1.52
Decreased appetite	1.35	Nail disorder	1.49
Alopecia	1.29	Dry eye	1.41
Stevens-johnson syndrome	1.24	Alopecia	1.34
Death	1.22	Nail toxicity	1.34
Neutropenia	1.14	Palmar-plantar erythrodysaesthesia syndrome	1.23
Acute kidney injury	0.98	Decreased appetite	1.16
Product use issue	0.95	Drug ineffective	1.12
Erythema	0.95	Blood phosphorus increased	1.12
Weight decreased	0.90	Dry skin	1.12